Education
About Us
Working with TipRanks
Follow Us
Can-Fite BioPharma (CANF)
:CANF
CANF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.98 - $4.69
Previous CloseN/A
Volume35.97K
Average Volume (3M)83.37K
Market Cap
$14.49M
Enterprise Value$5.00B
Total Cash (Recent Filing)$7.89M
Total Debt (Recent Filing)$104.00K
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Aug 28, 2025EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding12,977,183
10 Day Avg. Volume57,908
30 Day Avg. Volume83,369
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)3.73
Price to Sales (P/S)0.00
P/FCF Ratio-1.54
Enterprise Value/Market Cap345.01
Enterprise Value/Revenue1.85K
Enterprise Value/Gross Profit7.42K
Enterprise Value/Ebitda-159.37
Forecast
1Y Price Target
$4.50Price Target Upside309.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Can-Fite BioPharma News
PremiumCompany Announcements
Can-Fite BioPharma Announces June 2025 Shareholder MeetingPremiumCompany Announcements
Can-Fite BioPharma Secures $175 Million for Phase III Trials
PremiumCompany Announcements
Can-Fite BioPharma Gains FDA Compassionate Use Approval for Namodenoson
PremiumCompany Announcements
Can-Fite BioPharma Announces $3 Million Direct Offering
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
―
Mutual Funds
0.12% Other Institutional Investors
99.88% Public Companies and Individual Investors
CANF FAQ
What was Can-Fite BioPharma’s price range in the past 12 months?
Can-Fite BioPharma lowest stock price was $0.98 and its highest was $4.69 in the past 12 months.
What is Can-Fite BioPharma’s market cap?
Can-Fite BioPharma’s market cap is $14.49M.
When is Can-Fite BioPharma’s upcoming earnings report date?
Can-Fite BioPharma’s upcoming earnings report date is Aug 28, 2025 which is in 76 days.
How were Can-Fite BioPharma’s earnings last quarter?
Currently, no data Available
Is Can-Fite BioPharma overvalued?
According to Wall Street analysts Can-Fite BioPharma’s price is currently Undervalued.
Does Can-Fite BioPharma pay dividends?
Can-Fite BioPharma does not currently pay dividends.
What is Can-Fite BioPharma’s EPS estimate?
Can-Fite BioPharma’s EPS estimate is -0.11.
How many shares outstanding does Can-Fite BioPharma have?
Can-Fite BioPharma has 12,977,183 shares outstanding.
What happened to Can-Fite BioPharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Can-Fite BioPharma?
Currently, no hedge funds are holding shares in CANF
Company Description
Can-Fite BioPharma
Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company based in Israel, focused on the development of small molecule therapeutics for the treatment of autoimmune inflammatory diseases, oncology, and liver health. The company leverages its proprietary platform technology to develop its pipeline of drug candidates, which includes Piclidenoson, Namodenoson, and CF602, targeting conditions such as psoriasis, rheumatoid arthritis, liver cancer, and erectile dysfunction.
CANF Stock 12 Month Forecast
Average Price Target
$4.50
▲(309.09%Upside)